Patents by Inventor Michael L. Mohler

Michael L. Mohler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Estrogen receptor ligands and methods of use thereof
    Patent number: 9409856
    Abstract: The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBA compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including, inter alia, prevention and treatment of hormone-related diseases, cancers, inflammation, osteoporosis, peripheral vascular disease, reducing circulating lipid levels, and cardiovascular disease.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: August 9, 2016
    Assignee: Gtx, Inc.
    Inventors: James T. Dalton, Christina Herring, Duane D. Miller, Seoung-Soo Hong, Yali He, Michael L. Mohler, Ramesh Narayanan, Zhongzhi Wu
  • ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF
    Publication number: 20160031797
    Abstract: The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBA compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including, inter alia, prevention and treatment of hormone-related diseases, cancers, inflammation, osteoporosis, peripheral vascular disease, reducing circulating lipid levels, and cardiovascular disease.
    Type: Application
    Filed: June 8, 2015
    Publication date: February 4, 2016
    Inventors: James T. DALTON, Christina Herring, Duane D. MILLER, Seoung-Soo HONG, Yali HE, Michael L. MOHLER, Ramesh NARAYANAN, Zhongzhi WU
  • Nuclear receptor binding agents
    Patent number: 9078888
    Abstract: The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBAs are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, inflammatory diseases, oxidative stress related disorders such as Parkinson's and stroke, neurological disorders, ophthalamic disorders, cardiovascular disease, and obesity.
    Type: Grant
    Filed: January 22, 2008
    Date of Patent: July 14, 2015
    Assignee: GTX, INC.
    Inventors: James T. Dalton, Duane D. Miller, Michael L. Mohler, Seoung-Soo Hong, Zhongzhi Wu, Devesh Srivastava
  • Nuclear receptor binding agents
    Patent number: 8637706
    Abstract: The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: January 28, 2014
    Assignee: Gtx, Inc.
    Inventors: James T. Dalton, Christina Barrett, Duane D. Miller, Seoung-Soo Hong, Yali He, Michael L. Mohler, Ramesh Narayanan, Zhongzhi Wu
  • ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS
    Publication number: 20130116277
    Abstract: The present invention relates to a novel class of AKR1C3 inhibitors, to compositions containing them, to methods for their preparation, and to methods of use thereof. The AKR1C3 inhibitors may be useful in the treatment of, for example, prostate cancer, benign prostate hyperplasia (BPH), lung cancer, acne, seborrhea, hirsuitism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, uterine cancer, uterine fibroids, endometriosis, myeloma and leiomyoma.
    Type: Application
    Filed: September 7, 2012
    Publication date: May 9, 2013
    Inventors: James T. DALTON, Duane D. Miller, Ramesh Narayanan, Muralimohan Yepuru, Christopher C. Coss, Michael L. Mohler, Zhongzhi Wu
  • NUCLEAR RECEPTOR BINDING AGENTS
    Publication number: 20120157539
    Abstract: The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
    Type: Application
    Filed: January 31, 2012
    Publication date: June 21, 2012
    Inventors: James T. DALTON, Christina BARRETT, Duane D. MILLER, Seoung-Soo HONG, Yali HE, Michael L. MOHLER, Ramesh NARAYANAN, Zhongzhi WU
  • Nuclear receptor binding agents
    Patent number: 8158828
    Abstract: The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
    Type: Grant
    Filed: April 16, 2007
    Date of Patent: April 17, 2012
    Assignee: GTx, Inc.
    Inventors: James T. Dalton, Christina Barrett, Yali He, Seoung-Soo Hong, Duane D. Miller, Michael L. Mohler, Ramesh Narayanan, Zhongzhi Wu
  • Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
    Patent number: 8110562
    Abstract: This invention provides nuclear hormone receptor binding compounds, compositions comprising the same and methods of uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, prostate cancer and/or diseases or disorders of bone and muscle.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: February 7, 2012
    Assignees: University of Tennessee Research Foundation, The Ohio State University Research Foundation
    Inventors: James T. Dalton, Duane D. Miller, Igor Rakov, Casey Bohl, Michael L. Mohler
  • Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
    Publication number: 20110077221
    Abstract: This invention provides nuclear hormone receptor binding compounds, compositions comprising the same and methods of uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, prostate cancer and/or diseases or disorders of bone and muscle.
    Type: Application
    Filed: July 19, 2007
    Publication date: March 31, 2011
    Inventors: James T. Dalton, Duane D. Miller, Igor Rakov, Casey Bohl, Michael L. Mohler
  • Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
    Publication number: 20090156614
    Abstract: This invention provides new compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, prostate cancer, muscle wasting diseases and/or disorders or a bone-related diseases and/or disorders.
    Type: Application
    Filed: July 19, 2007
    Publication date: June 18, 2009
    Inventors: James T. Dalton, Duane D. Miller, Igor Rakov, Casey Bohl, Michael L. Mohler
  • Nuclear receptor binding agents
    Publication number: 20090062341
    Abstract: The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
    Type: Application
    Filed: November 28, 2006
    Publication date: March 5, 2009
    Inventors: James T. Dalton, Christina Barrett, Yali He, Seoung-Soo Hong, Duane D. Miller, Michael L. Mohler, Ramesh Narayanan, Zhongzhi Wu
  • Nuclear receptor binding agents
    Publication number: 20090030036
    Abstract: The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBAs are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, inflammatory diseases, oxidative stress related disorders such as Parkinson's and stroke, neurological disorders, ophthalamic disorders, cardiovascular disease, and obesity.
    Type: Application
    Filed: January 22, 2008
    Publication date: January 29, 2009
    Inventors: James T. Dalton, Duane D. Miller, Michael L. Mohler, Seoung-Soo Hong, Zhongzhi Wu, Devesh Srivastava